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Fever is frequently observed in cancer patients treated 
with high-dose recombinant human interleukin-2 (rIL-2). 
The preincubation of rlL-2 with polymyxin B, an antibi­
otic that inhibits the biologic effects of endotoxins, did 
not diminish the pyrogenicity of IL-2 in New Zealand 
rabbits, indicating that IL-2-induced fever is not due to 
contaminating endotoxins. In contrast to interleukin-1 
(IL-1), tumor necrosis factor (TNF), and interferon a, 
which cause fever through their effects on arachidonic 
acid metabolism in the hypothalamus, IL-2 was unable to 
induce prostaglandin E2 synthesis in hypothalamic cells 
or fibroblasts in vitro, suggesting that IL-2 is not intrinsi­
cally pyrogenic. To determine if IL-2-induced fever is 
mediated indirectly through the generation of pyrogenic 
cytokines, culture supernatants from IL-2-stimulated hu­
man peripheral blood mononuclcar cells were screened 
for the presence of pyrogens by direct injection into 
rabbits and by measuring the amounts of IL-1 a, IL-10, 
and T N Fa by specific radioimmunoassays (RIA). All 
three cytokines were readily detected by RIA in these 
supernatants, which in turn caused fever when injected 
into rabbits. Furthermore, in six of six cancer patients 
treated with rIL-2, elevated levels o f TNFa were de­
tected in the plasma by RIA 2 hr after IL-2 administra­
tion; Plasma TNF levels increased from pretreatment 
values of 14 ± 7 to 765 ± 150 pg/ml 2 hr after an IL-2
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injection. These results strongly implicate IL-2-induced 
pyrogenic cytokines, in particular TN Fa, as a major 
cause of the fever and possibly other aspects o f  the 
acute-phase response associated with IL-2 therapy.
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INTRODUCTION
Cancer patients undergoing treatment with high- 
dose recombinant interleukin-2 (rIL-2) develop an 
array of potentially life-threatening side effects in­
cluding chills, fever, and hypotension beginning 
approximately 2 hr after initiating therapy (1-5). 
Although the concomitant administration of antipy­
retics usually suppresses IL-2-induced fever, tem­
peratures in excess of 42°C have been recorded in 
some patients. The administration of IL-2 also 
causes marked elevations in the serum levels of 
hepatic acute-phase proteins and stress-related pi­
tuitary hormones (1, 6). Whether these diverse 
systemic effects can be attributed directly to the 
IL-2, to detergents or contaminating endotoxins in 
the IL-2 preparations, or to cytokines generated in 
response to IL-2 is uncertain. The late onset of 
fevei- after an IL-2 injection; the ability of IL-2 to 
stimulate the synthesis of interferon 7, lymph oto- 
xin, and tumor necrosis factor (TNF) in cultured 
peripheral blood mononuclear cells (PBMC) (7, 8); 
and the ability of TNF to induce fever in both 
experimental animals (9) and humans (10) support 
the view that IL-2-induced pyrogenic cytokines 
may be responsible for at least some of the toxic 
effects attributed to IL-2.
To assess the contribution of IL-2-induced pyro­
gens to the toxicity of IL-2 treatment, we employed
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radioimmunoassays for TNFa and IL-la and IL-1 (5 
to quantitate these cytokines both in culture super­
natants of IL-2-activated PBMC and in the plasma 
of cancer patients treated with IL-2. Our studies 
indicate that IL-2 is not intrinsically pyrogenic, nor 
is its ability to cause fever in experimental animals 
due to contaminating endotoxins. On the other 
hand, our data demonstrate that the administration 
of IL-2 results in the prompt release of TNFa into 
the circulation and suggest that this inducible pyro­
gen may be responsible for the fever and other side 
effects associated with IL-2 treatment.
MATERIALS AND METHODS
Cytokine Preparations
Human rIL-2 was provided as a lyophilized pow­
der by Cetus Corporation, Emeryville, CA. The 
preparation utilized in the in vitro studies and in the 
animal pyrogen experiments was identical to the 
material undergoing evaluation in cancer patients at 
our institution. The biological activity of the IL-2 
was confirmed in our laboratory using a standard 
3H-thymidine incorporation assay with phytohe­
magglutinin (PHA)-activated human T lympho­
blasts (11), and the concentration yielding 50% 
maximal incorporation (1 U/ml) was 0.3 ng/mL All 
preparations contained less than 0.01 ng of endo­
toxin/mg protein as determined by the Limulus 
assay. The IL-2 was reconstituted immediately 
prior to use in pyrogen-free sterile water and diluted 
to the appropriate concentration in sterile saline or 
tissue culture medium. A proprietary mixture of 
sodium dodecyl sulfate and mannitol present in the 
IL-2 formulation, henceforth referred to as exci­
pient, was also provided by Cetus Corporation to 
serve as an experimental control. Interleukin-1 (IL- 
1) was purified to homogeneity from the condi­
tioned media of human monocytes exposed to heat- 
killed Staphylococcus albus (12). Recombinant 
IL-la and IL-1 (3 were kindly provided by Hofifman- 
LaRoche and Cistron Biotechnology, Inc., Pine 
Brook, NJ, respectively. TNFa was obtained from 
Genentech, Inc., South San Francisco, CA.
Preparation o f PBMC Conditioned Media
Human PBMC were obtained from the hepari- 
nized venous blood of healthy donors by density- 
gradient centrifugation with lymphocyte separation 
medium (Litton), washed, and resuspended at a
Jer y f j *  lo6; » l  in minimal essential 
medium (MEM) containing 1% heat-inactivated feu-: 
man AB serum (MA Bioproducts, WalkersviUe, 
MD). The cells were incubated overnight at 37°C in. 
a 5% C 02 atmosphere in the presence of 100 ng/ml 
endotoxin (Sigma) or 10 (xg/ml polymyxin B (Pfizer) 
with various concentrations of rIL-2 ranging from 0 
to 103 U/ml in 5-ml aliquots in 50-ml polypropylene 
centrifuge tubes (Corning). The cells were then 
removed by centrifugation at 500g for 10 min and
the supernatants frozen at-70°C until used.
Pyrogen Assays
Female albino New Zealand rabbits weighing 
approximately 2 kg were obtained from a single 
supplier and trained for pyrogen testing as previ­
ously described (13). Core temperatures were mea­
sured using indwelling rectal thermistors (Yellow 
Spring Instruments, Yellow Spring, OH) and re­
corded at 1-min intervals on a Digistrip II printer 
(Kaye Instruments, Bedford, MA). Baseline rabbit 
rectal temperatures were determined by computing 
the mean temperature over an interval ranging from 
30 min before to 10 min after the injection of the 
material being assayed. Fever was measured rela­
tive to the mean baseline temperature. Rabbits were 
baseline temperatures varying more than 0.3°C 
were not used. All materials administered as an 
intravenous bolus injection were warmed to 39°C 
before injection and injected volumes did not ex­
ceed 20 ml. In several experiments, rIL-2 was 
administered as a prolonged intravenous infusion 
into a lateral ear vein utilizing a syringe infusion 
pump (Harvard Apparatus Co., Dover, MA) 
adjusted to inject at a rate of 6 ml/hr. In some 
experiments, the rabbits received ibuprofen 
(Upjohn), 10 mg/kg, as abolus injection followed by 
a continuous infusion at a rate of 1.0 mg/kg/hr in 
addition to IL-2. Recombinant IL-2 was also prem- 
cubated for 2 hr at 39°C with 10 jig/ml polymyxin B 
to inactivate endotoxins b e f o r e  injection into ra 
bits (14). In these studies, the IL-2 preparationi was 
diluted to a concentration of less than 40,000 m
before adding the antibiotic.
Prostaglandin E2 (PGE2) Assays
Rabbit hypothalamic minces prepared as previ­
ously described (15) as well as human foresk 
fibroblasts and PBMC were used to test the ability
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of rIL-2 to induce prostaglandin E2 (PGE2) synthe­
sis in vitro. The fibroblasts were cultured in RPMI 
1640 medium containing 10% heat-inactivated fetal 
calf serum and were split every 4 days. The fibro­
blasts were utilized as indicator cells after 3 weeks 
in culture and were at 50% confluence at the time of 
the assays. The cells were washed in MEM and 
incubated at 37°C for 4 hr in MEM containing 10 fjig/ 
ml polymyxin B and the appropriate dilution of 
rIL-2 or other cytokine. The supernatants were 
collected and frozen at -70°C until assayed. The 
PGE2 assays were performed in duplicate using a 
specific radioimmunoassay (Seragen, Boston, MA) 
and the results are expressed as picograms of PGE2 
per 104 fibroblasts. Human PBMC were cultured 
overnight at a density of 106 cells/ml in MEM 
containing \%  AB serum and either rIL-2 or a 
suspension of heat-killed Staphylococcus albus. 
These supernatants were similarly assayed and the 
results are expressed as picograms of PGE2 per 
milliliter of culture medium.
Clinical Specimens
Serial plasma samples for the human studies were 
obtained from cancer patients enrolled in an ongo­
ing Phase II clinical trial with rIL-2 and autologous 
lymphokine-activated killer (LAK) cells. Patients 
were initially treated with rlL-2 alone at a dose of 
100,000 U/kg by brief intravenous infusions every 8 
hr for 3 consecutive days. Unless otherwise stated, 
the plasma samples for this investigation were ob­
tained after the first injection. After a 36-hr respite, 
the patients were subjected to four consecutive 
daily leukaphereses and the harvested PBMC were 
cultured in rIL-2-supplemented medium as de­
scribed by Rosenberg et al. {3). The 1L-2 treatment 
was then resumed as a continuous infusion admin­
istered in conjunction with the LAK cells. This trial 
was previously approved by the Human Investiga­
tion Review Board at the New England Medical 
Center, and all study participants gave prior in­
formed consent.
Cytokine Radioimmunoassays (RIAs)
Blood samples for the TNF and IL-1 RIAs were 
collected in 7-ml vacuum-sealed tubes containing 
10.5 mg of EDTA and 3.5 trypsin inhibitor units of 
aprotinin (Sigma). The samples were first centri­
fuged at 500# for 15 min, the plasma was removed,
and then the samples were subjected to a second 
centrifugation at 10,000# for 4 min to eliminate 
residual platelets. All plasma samples were stored 
at -20°C until assayed.
TNFa levels in plasma and culture supernatants 
were measured by a competitive inhibition RIA 
(16). Recombinant TNFa standards were prepared 
at concentrations ranging from 5 pg/ml to 5 ng/ml in 
an RIA buffer containing 0.01 M  Na phosphate, 
0.25% bovine serum albumin (BSA), and 0.05% Na 
azide in 0.15 M NaCl, pH 7.4. Triplicate 100-jxl 
aliquots of plasma, culture supernatants, TNF stan­
dards, or buffer alone were mixed with 300 jxl of 
0.3% normal rabbit serum (NRS) and 100 |Jtl of 
diluted rabbit anti-TNF antiserum in 10 x 75-mm 
polystyrene tubes. The anti-TNF antiserum used in 
these assays was generated in rabbits by repeated 
immunization with recombinant human TNFa. 
Samples were incubated for 24 hr at room temper­
ature. Radiolabeled TNF was prepared using a 
modified chloramine T technique. One hundred 
microliters of 125-I-TNF (7 x 105 cpm/ml, 10 [xCi/ 
jxg) was then added to the assay tubes. After 
another 24-hr incubation, 700 \\X of a 6% polyethyl­
ene glycol (6000 MW) solution containing 1.4% 
sheep anti-rabbit IgG (Sigma) was added to each 
sample. Precipitable immune complexes were col­
lected by centrifugation for 15 min at lOOOg. Fol­
lowing the decantation of the supernatants, the 
radioactivity of the pelleted material was deter­
mined with a Beckman 4000 gamma counter. All 
samples were assayed in triplicate and standard 
errors were less than 6%. This RIA does not detect 
IL-1 or TNF(3 (lymphotoxin) (16). The concentra­
tions of IL-la and IL-1 (3 in plasma and culture 
supernatants were also measured by RIA (17, 18).
IL-1 Bioassay
Plasma IL-1 levels were measured as previously 
described (19). Heparinized blood was obtained 
prior to and 2, 4, and 8 hr after the first IL-2 
injection and the plasma separated and frozen at 
-70°C. Plasma(0.3 ml) was applied toa 1 x 30-cm 
column of autoclaved packed Sephadex G50-fine 
(Pharmacia) previously equilibrated with sterile 
RPMI 1640 medium containing 0.1% BSA and 10 
(jig/ml polymyxin B. Fractions of 0.6 ml were col­
lected and assayed in quadruplicate for proliferative 
activity in a 3H-thymidine incorporation assay using 
as indicator cells a subclone of the murine D10.G4.1
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helper T-cell line specifically selected for its high 
level of sensitivity to IL-1 (20). The active fractions 
(numbers 16-19) from the gel filtration column were 
pooled. In order to reduce the IL-2 concentration, 
the pooled fractions were then passed over an IL-2 
affinity column. The anti-human rIL-2 antibody 
used in the preparation of the affinity gel was raised 
in a New Zealand rabbit by repeated multiple-size 
subcutaneous injections of rIL-2 suspended in 
Freund’s adjuvant. Hyperimmune IgG was isolated 
from a 47% ammonium sulfate precipitate of serum 
using protein A agarose (Genzyme, Boston, MA) 
affinity chromatography and immobilized by cyan­
ogen hromide-activated Sepharose 4B (Pharmacia, 
Piscataway, NJ). This neutralizing anti-human 
rIL-2 IgG was readily detected in a rIL-2 enzyme- 
linked immunosorbent assay (ELISA) using a goat 
anti-rabbit IgG antibody (Hyclone, Logan, UT) as 
the indicator antibody. The affinity gel contained 5 
mg IgG/ml gel. Columns containing 0.5 ml of gel 
were prepared in Pasteur pipettes. Pooled fractions 
16-19 from both pretreatment and posttreatment 
plasma samples were slowly passed over the col­
umns. Nonbinding material was free of IL-2 as 
determined by ELISA (InterTest-2, Genzyme, Bos­
ton). The nonbinding, IL-2-depleted, material 
(flow-through) was then incubated overnight with 
1% NRS or an anti serum generated against human 
monocyte-derived IL-1 (12) and subsequently as­
sayed as above for proliferative activity with 
D10.G4.1 cells. All 3H-thymidine incorporation as­
says were performed in quadruplicate and standard 
deviations were consistently less than 5%.
RESULTS
Pyrogenicity o f rIL-2 in Rabbits
As shown in Fig. I , a bolus injection of 400,000 U 
(120 |xg)/kg of rIL-2 produced a monophasic fever in 
rabbits which began after a latent period of 60 min 
and reached maximal elevation 90 to 120 min after 
the injection. The fever was unaffected by prior 
incubation of the rlL~2 with polymyxin B. In con­
trast, rIL-1 3 (100 ng/kg) induced an immediate 
fever which reached peak elevation 50 min after the 
injection.
As shown in Fig. 2, the administration of rIL-2 at 
a rate of 100,000 U (30 jxg/kg/hr induced a progres­
sive rise in core temperature in rabbits beginning 
approximately 2 hr after initiating and continuing 
throughout the infusion. Temperature increments
Zealand rabbits were treated with 400,000 U/kg rIL-2 alone ( • )  
or IL-2 preincubated with the endotoxin-binding antibiotic poly* 
myxin B (O) òr with monocyte-derived IL-1 (□). IL-2-associated 
fever is delayed relative to that induced by IL-1 and is not 
diminished by preincubation of the IL-2 with polymyxin B. 
Numbers in parentheses indicate the number of animals in each 
treatment group.
ranging from 0.35 to 2.85°C were recorded in indi­
vidual rabbits 4 hr after beginning the infusion. The 
induction of fever was prevented by intravenous 
ibuprofen. The infusion of excipient material at a 
rate equivalent to the dose received by the 1L-2- 
treated animals did not cause fever. Infusions of 
rIL-2 at a dose of 10,000 U/kg/hr were likewise 
nonpyrogenic. .
Efforts to detect circulating pyrogens by direct 
plasma transfer were unsuccessful. In these exper­
iments, 20 ml of heparinized plasma taken from
- 0.6 -
Time (hr) o
Fig. 2. Mean febrile response
uous infusion. New Zealand r a b b i t s  treat „rt,v(tnieA bv the 
rIL-2 developed fever ( • )  Anima(s treited
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febrile rabbits 2 hr after an IL-2 injection (400,000 
U/kg) was injected into other rabbits. Only one of 
seven rabbits so treated developed more than a 
0.25°C temperature increase. Conversely, plasma 
obtained 2 hr after a bolus injection of endotoxin 
from animals with temperature elevations compara­
ble to those of the IL-2-treated rabbits produced 
prompt febrile responses in the recipient rabbits 
characteristic of the fever resulting from endoge­
nous pyrogens, (data not shown).
Cytokine-Induced Prostaglandin E2 (PGE2) 
Synthesis
We previously demonstrated that recombinant 
human IL-2 at concentrations up to 500 U/ml does 
not induce PGE2 synthesis in cultured rabbit hypo­
thalamus cells (21). Identical results were obtained 
with the rIL-2 preparations currently in use in the 
various IL-2/LAK-cell clinical trials under way at 
our institution (data not shown). To determine if 
these négative results with human IL-2 and rabbit 
indicator cells were a consequence of an unsus­
pected species specificity, human foreskin fibro­
blasts and PBMC were exposed to various concen­
trations of IL-2 and the conditioned media assayed 
for PGE2. As shown in Table I, rIL-2 at concentra­
tions ranging up to 10,000 U/ml failed to induce 
PGE2 synthesis in the fibroblasts, whereas IL-1 was 
consistently positive in these assays. Human 
PBMC, on the other hand, produced PGE2, but only 
in response to high concentrations (1000 U/ml) of 
rIL-2 or to opsonized Staphylococcus albus. As 
demonstrated below, elevated levels of PGE2 from 
PBMC stimulated with high concentrations of rIL-2 
for 24 hr are likely secondary to the coinduction of 
IL-1 and TNF.
IL-2-Induced Pyrogenic Cytokines in PBMC 
Culture Supernatants
Human PBMC produce several cytokines when 
exposed to high concentrations of rIL-2 (7, 8). In 
the present studies, we injected rabbits with rIL-2- 
stimulated PBMC culture supernatants and ob­
served rapid-onset monophasic fevers characteris­
tic of the response to endogenous pyrogens (Fig. 3). 
In these experiments, the PBMC were incubated for 
18 hr in the presence of 500 U/ml of rIL-2 and the 
amount of rIL-2 contained in the injected superna-
Table I. Induction of PGE2 Synthesis
Human foreskin fibroblasts
Culture medium
p g e 2
Expt 1
(pg/ml/104 cells)
E xpt 2
Control 52 13
IL-1 (100 pg/ml) 2600 OOO
IL-2 (U/ml)
1 105 0
10 72 32
100 70 53
1,000 86 50
10,000 53 68
Excipient ND 0
Human PBMC
PGE2 (pg/ml)
Culture medium Expt 1 E xpt 2
Control 0
Staphylococcus albus 140 520
IL-2 (U/ml)
1 0 0
10 0 0
100 0 0
1,000 390 0
10,000 680 360
tant was less than 5000 U, well below the amount o f  
IL-2 required to produce fever when injected alone 
(21).
The pyrogenic culture supernatants were also 
assayed for IL-1 a, IL-1 (3, and TNFa using RIAs 
specific for each cytokine. Asdepicted in Table II, 
the unstimulated PBMC from three human donors 
produced low or undetectable levels of the three 
cytokines, but after exposure to 1000 U/ml of rIL-2, 
the PBMC secreted large quantities of TN Fa and 
IL-lp. IL-2-induced secretion of IL-lot was consis­
tently less than that of IL-1 (3 and TNFa. These 
increases were comparable to those induced by 10 
ng/ml of bacterial endotoxin. These cytokines in­
duced by rIL-2 may explain the elevated PGH2 
levels in the culture supernatants of PBMC stimu­
lated with high concentrations of rIL-2 (Table I).
IL-2'Induced Circulating Pyrogens in Humans
Because of the relative insensitivity of the rabbit 
pyrogen assay, RIAs specific for various human 
cytokines were employed in an effort to detect 
pyrogenic substances in the plasma of cancer pa­
tients participating in ongoing IL-2 clinical trials. 
Plasma samples obtained before and 2, 4, and 8 hr
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No IL-2 IL-2 
Fig. 3. Pyrogenicity of PBMC culture supernatants. Ten millili­
ters of culture supernatant from unstimulated PBMC or from 
cells incubated at 3 x 106 cells/ml in medium containing 500 0 / 
ml rlL-2 was injected into rabbits. Animals treated with the 
supernatant from rlL-2-activated PBMC developed a prompt 
febrile response, whereas those treated with the conditioned 
medium from the unstimulated cells remained afebrile AT  was 
recorded at 1 hr postinjection.
after an injection of 100,000 U/kg rIL-2 were as­
sayed for IL-la and IL-10 and TNFa using the 
RIAs described under Materials and Methods. 
Plasma concentrations of TNFa rose from pretreat­
ment levels of 14 ± 7 to 765 ± 150 pg/ml within 2 hr 
after an IL-2 injection and subsequently declined
Table II. IL-2-Induced Secretion of IL-I and TNF by PBMC*
Cytokine concentration (ng/ml)
Medium
control21
IL-2 
(1000 U/ml*
Endotoxin 
(10 ng/ml)
Expt 1 
]L -la <0.1 0.7 1.2
IL -lp 0.8 6.1 12.0
TN Fa 0.4 6.6 3.1
Expt 2 
IL -la <0.1 3.9 0.8
IL -tp <0.1 6.8 5.2
TN Fa <0.1 4.8 3.6
Expt 3 
IL -la <0.1 5.3 2.7
IL -lp <0.1 16.0 22.0
"Cells were cultured for 18 hr at a density of 5 x 106/ml. 
kpBMC cultures with medium alone or with IL-2-suppIemented 
medium contained 5 polymyxin B.
toward baseline in each of the patients studied (Fig; 
4), This time course is similar to that of the febrile 
response to IL-2 reported in earlier Phase I studies* 
in which antipyretics were not routinely adminis­
tered (1, 2). In some patients, additional plasma 
samples were obtained at 24,48, and 72 hr after the 
first IL-2 injection, and in none of these samples did 
the TNFa levels revert to baseline, indicating that 
TNF was present in the circulation throughout the 
entire 3 days of IL-2 treatment. In contrast, plasma 
levels of IL-la remained below the limits of detec­
tion of the RIA (data not shown).
As shown in Fig. 5, IL-10 (>100 pg/ml) was 
detected in the pretreatment plasma of all study 
participants. However, in contrast to the TNFa 
levels, the plasma concentration of IL-1 (3 changed 
only minimally during the 8-hr sampling period. The 
high pretreatment plasma levels of IL-1 (3 and the 
failure of IL-2 injections to increase the plasma 
IL-lfl levels to the same extent as the TNFa levels 
also contrast with the in vitro data, which failed to 
demonstrate IL-1 production by unstimulated 
PBMC and which showed comparable amounts of 
IL-10 and TNFa in PBMC culture supernatants 
after 24 hr of exposure to IL-2.
To verify that the immunoreactive material de­
tected in the plasma with the IL-ip RIA was 
biologically active, a highly sensitive bioassay for 
IL-1 using a subclone of the murine D10.G4.1 
helper T-cell line was employed (20). This assay 
detects concentrations of'IL-1 100-fold lower than 
the threshold for the RIA. Although highly sensitive 
to IL-1, these cells also respond to IL-2, IL-4, and 
possibly other cytokines (22). High molecular 
weight inhibitors of IL-1-induced T-cell prolifera­
tion (19, 23) were first removed from the plasma 
samples by gel filtration. Bioassays of gel filtration 
fractions from plasma obtained from these patients 
at various intervals after an injection of rIL-2 re­
vealed a peak of activity in fractions corresponding 
to a molecular weight range of 15-25 kD (Fig. 6). 
Because of the sensitivity of the D10.G41 cells to 
IL-2, the active gel filtration fractions (numbers 16- 
19) were pooled and then passed over an IL-2 
affinity column, which reduced the IL-2 concentra­
tion to undetectable levels in the IL-2 ELISA. The 
IL -2 -d ep le ted  material was incubated with normal 
rabbit serum or a neutralizing anti-IL-1 rabbit anti­
serum and then assayed for proliferative activity 
with the D10.G4.1 cells. Despite the marked differ­
ence between the gel filtration profile of the pre-
Journai o f Clinical Immunology, Vol. 8, No. 6, ¡988
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Fig. 4. Plasma tumor necrosis factor (TNF) levels after an injection of rIL-2. Serial plasma samples were obtained 
before and 2,4, and 8 hr after an injection of 100,000 U/kg rIL-2 from six consecutively treated patients, and TNF 
levels in the plasma determined by RIA. in each patient, the IL-2 injection gave rise to a prompt increase in the 
plasma concentration of TNF.
treatment plasma and those obtained after an IL-2 
injection (Fig. 6), the proliferative activities of the 
affinity gel flow-through fractions were relatively 
constant throughout the 8 hr of plasma sampling 
(Fig. 7). Nearly all of the biological activity of the 
pooled gel filtration fractions derived from the 2-, 
4-, and 8-hr plasma samples was eliminated by the 
affinity gel, indicating that most of the activity of 
these fractions in the bioassay was due to residual 
IL-2 and not to IL-1 induced by the treatment. 
Pretreatment samples were active in the bioassay 
and their proliferative activity was partially neutral­
ized by an IL-1 antibody (Fig. 7). These results 
indicate that small amounts of IL-1 may be pro­
duced constitutively, independent of a specific in­
ducer such as IL-2.
The affinity gel flow-through fractions assayed in 
Fig. 7 contained TNF by RIA and were free of 
exogenous IL-2 and high molecular weight inhibi­
tors of lymphocyte proliferation. The failure of the 
bioassay to demonstrate an increase in the IL-1 
concentration of the fractions generated from 
postinjection plasma that is comparable with the
increase in plasma TNF levels corroborates the 
RIA data. In contrast to TNF, which is released 
promptly into the circulation after an IL-2 injection, 
IL-1 levels may not appreciably increase or do so 
only several hours after an IL-2 injection.
DISCUSSION
Despite the efficacy of IL-2 as an antineoplastic 
agent, the initial enthusiasm for its widespread use 
in cancer patients has somewhat abated as a conse­
quence of its severe toxicity. Although low doses of 
IL-2 are generally well tolerated, high doses are 
associated with a multitude of side effects including 
chills, fever, and confusion as well as potentially 
lethal effects such as hypotension, myocardial in­
farction, renal and hepatic failure, and fluid reten­
tion resulting in massive weight gain and pulmonary 
edema (1-5). Patients treated with high doses of 
IL-2 also develop increased serum levels of hepatic 
acute-phase reactants and hypothalamic-pituitary 
hormones otherwise associated with the metabolic 
response to infection and inflammation (2,6).
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Time (hr)
Patient
Fig. 5. Plasma IL -ip levels after an injection of rIL-2, As in Fig. 4, the serial plasma samples were obtained at various 
intervals after an injection of 100,000 U/kg rIL-2. The IL-lp levels were determined by RIA. Pretreatment levels of IL-10 
were much higher than those of TNFa. However, the plasma concentrations of IL-10 were much less affected than the TNF 
levels by the administration of rIL-2.
These toxic effects of rIL-2 could be attributed to 
residual endotoxin, although only extremely low 
levels (<0.01 ng/mg protein) have been detected 
with the Limulus assay. Several investigators have 
reported that endotoxin at concentrations below the 
threshold of the Limulus assay is capable of acti­
vating monocytes to produce the pyrogen interleu­
kin-1 (24, 25). Therefore, to determine if residual 
endotoxin in the IL-2 preparations might be respon­
sible for IL-2-associated fever, IL-2 was preincu­
bated with polymyxin B prior to injection. The 
inability of polymyxin B to reduce the pyrogenicity 
of IL-2 in New Zealand rabbits suggests that the 
fever associated with IL-2 is due to the lymphokine 
itself or to IL-2-induced pyrogens rather than con­
taminating endotoxins.
The fever associated with IL-2 is clearly dose 
dependent. In a recently completed dose escalation 
Phase I clinical trial in cancer patients, fever was 
not observed after a single bolus injection of IL-2 
until doses in excess of 250,000 U/M2 (approxi­
mately 6500 U/kg) were reached (2). In New Zea­
land rabbits, neither a bolus injection of 10,000 U/kg
(21) nor a continuous infusion of 10,000 U/kg/hr 
induced fever, whereas 100,000 U/kg/hr was pyro- 
genic. An injection of 400,000 U (120 |xg)/kg gener­
ally induces a temperature increase of less than 1°C, 
an increment readily achieved with only 100 ng/kg 
of IL-1 (26), indicating that IL-2 is less than 1/1000 
as potent a pyrogen as IL-1.
We previously demonstrated that rIL-2 does not 
induce PGE2 synthesis in cultured rabbit hypothal­
amus cells (21). These findings were felt to indicate 
that IL-2 was not an intrinsic pyrogen capable of 
interacting directly with the hypothalamus, as is the 
case with IL-1, IFNa, and TNF (9, 15, 27). Al­
though human rIL-2 will support the growth of 
activated T cells from virtually all species, it is 
conceivable that its effects on arachidonic acid 
metabolism might be s p e c i e s  specific. Therefore, 
our previous experiments were repeated employing 
human fibroblasts. These studies showed that IL- 
treated, but not IL-2-treated, fibroblasts synthe­
sized PGE2 (Table I). S t u d i e s  with human PBMC 
yielded similar results e x c e p t  when high concen ra­
tions of IL-2 were e m p lo y e d . P B M C  stimulated
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Fig. 6. Proliferative response of DIO cells to cytokines in the 
plasma of patients treated with rIL-2. Plasma samples obtained 
before ( • )  and 2 hr (O), 4 hr (□), and 8 hr (■) after an injection 
of 100,000 U/kg rIL-2 were fractionated on a Sephadex G50 
column and the gel filtration fractions assayed in a 3H-thymidine 
incorporation assay with murine D10 lymphoblasts as indicator 
cells. A 15- to 25-kilodaIton peak of proliferative activity was 
evident in all o f the postinjection plasma samples. The elution 
points and molecular weights (kilodaltons) of the various stan­
dards are indicated by arrows.
with either opsonized Staphylococcus albus or 1000 
U/ml IL-2 synthesized PGE2; however, these su- 
pernatants were pyrogenic in rabbits and contained 
both TNFa and IL-1, both of which are potent 
inducers of PGE2 synthesis (9), suggesting that the 
effect of IL-2 on PGE2 synthesis by PBMC may 
have been mediated by TNF and IL-1 generated in 
response to IL-2.
Compared with the fever associated with IL-1, 
TNF, or IFNa, that induced by IL-2 is uniquely 
delayed in onset, beginning approximately 1 hr after 
a bolus injection in rabbits and reaching peak ele­
vation 30-40 min later. Fever is evident within 10 
min and reaches maximal levels 45 min after an 
injection of IL-1 or TNF (9, 26). The delayed onset 
of lL-2-induced fever and the inability of IL-2 
directly to induce PGE2 synthesis argue against its 
being an endogenous pyrogen; on the other hand, 
the data suggest that IL-2-associated fever may be 
mediated through the induction of bona fide pyro­
genic cytokines.
Several experiments were carried out to deter­
mine if pyrogenic substances could be detected in 
the plasma after an IL-2 injection. The transfer of 
plasma from febrile endotoxin-treated rabbits is
r
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Fig. 7. Proliferative response of D10 lymphoblasts to IL-2- 
depleted gel filtration fractions from the serial plasma samples of 
two IL-2 recipients. Pooled biologically active fractions from the 
Sephadex G50 column were depleted of IL-2 by passage over an 
affinity column of Sepharose-immobilized IgG from a rabbit 
hyperimmune to rIL-2. The fractions were incubated overnight 
in 1% normal rabbit serum (A) or IL-1 antiserum (B) and assayed 
for proliferative activity in the D10.G4.1 bioassay. Background 
3H-thymidine incorporation in unstimulated cells is indicated by 
the horizontal line. The partial neutralization of the activity of 
the lL-2-depleted fractions by an anti-IL-1 antibody indicates 
that at least a portion of the remaining activity was due to IL-1. 
However, no consistent increase in proliferative activity o r in the 
extent to which the activity was neutralized by the IL-1 antibody 
was observed in IL-2-depleted fractions derived from plasma 
serially obtained after an IL-2 injection.
known to cause fever in the recipient animals. Our 
transfer experiments with IL-2-treated animals 
serving as the plasma donors failed to demonstrate 
circulating pyrogenic material, presumably because 
of the low sensitivity of the rabbit pyrogen assay. 
For these reasons, we employed highly sensitive 
RIAs to study IL-2-induced pyrogens. As shown in 
Table II, both IL-1 and TNF (8, 28) are generated 
by PBMC in response to IL-2 in the absence of 
endotoxin and could therefore play a causative role 
in IL-2-induced fever. Because the antibodies to 
IL-1 and TNF utilized in the respective RIAs were 
raised in rabbits by immunization with recombinant 
human cytokines, we were unable to employ these 
RIAs to detect circulating pyrogens in rabbits with 
fever due to IL-2. However, in human subjects, we
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clearly detected circulating immunoreactive TNF 
following IL-2 administration; furthermore, the ki­
netics of the TNF release into the circulation were 
consistent with onset of fever in IL-2-treated hu­
mans not receiving antipyretics. Conversely, the 
RIAs for IL-la and IL-13 failed to demonstrate a 
comparable increase in the plasma level of either 
cytokine, despite their readily demonstrable induc- 
ibility in vitro.
Cannon et al. reported that the low molecular 
weight fractions of gel-filtered plasma from healthy 
human donors were active in thymocyte prolifera­
tion assays and that the biological activity of these 
fractions was inhibited by anti-IL-1 antibodies, re­
sults suggesting that IL-1 is produced constitutively 
in vivo (29). The constitutive expression of IL-1 
genes has also been demonstrated by Northern 
analysis of RNA extracted from lymphoid tissue 
from pathogen-free mice (30). Although our inves­
tigation did not specifically compare plasma IL-1 
levels of healthy donors with those of cancer pa­
tients, both the RIA and the bioassay results indi­
cate that at least a modest amount of IL-lp is 
produced constitutively in patients with dissemi­
nated malignancy.
As shown in Fig. 5, we were able to document 
only a modest increase in immunoreactive IL-13 
levels in the plasma after a IL-2 injection. Likewise, 
as shown in Fig. 7, we were unable to show that 
IL-2 treatment altered the proliferative activity of 
fractionated plasma that could be attributed to IL-I 
to the same degree that it increased the TNF levels. 
Given the low levels of proliferative activity on the 
highly IL-1-sensitive DIO.(34.1 cells, we conclude 
that IL-1 may not be one of the cytokines rapidly 
released into the circulation following high-dose 
IL-2 therapy in cancer patients. This conclusion is 
supported by the observation that PBMC stimu­
lated with IL-2 in vitro rapidly release TNFa into 
the culture supernatant, whereas the secretion of 
IL-1 is scarcely detectable in the first few hours 
(31). Both IL-la and IL-10 are initially produced as 
35-kD precursors, which are subsequently cleaved 
to generate the 17-kD species found in culture 
supernatants. The delay associated with the proc­
essing of IL-1 as well as the fact that IL-I (espe­
cially IL-la) remains, to a large extent, cell associ­
ated regardless of the inducing agent (31) may 
account for our failure to detect IL-1 in the plasma 
within a few hours of an IL-2 injection, when
circulating TNFa is readily demonstrable and the 
patient already febrile and hypotensive.
We conclude from these studies that IL-2 does 
not directly stimulate the hypothalamic fever mech­
anism but rather induces circulating TNF and that 
this cytokine may be primarily responsible for the 
initial febrile response to IL-2 treatment. The dra­
matic and sudden increase in circulating TNF levels: 
2 hr following an IL-2 injection is temporally con­
sistent with the onset of fever as well as some of the 
other toxic manifestations of IL-2. The contribution 
of other pyrogenic cytokines such as TNFfJ (lym- 
photoxin) to the toxicity of IL-2 treatment is yet to 
be determined. These studies await the availability 
of highly sensitive and specific assays.
In addition to its potential role as a direct medi­
ator of IL-2 toxicity, TNF may also contribute to 
the antineoplastic effects of IL-2 treatment. TNF 
increases the expression of IL-2 receptors on large 
granular lymphocytes and enhances their tumori- 
cidal activity (32). TNF affects the interaction of 
leukocytes with endothelial cells (33) and may 
therefore influence the trafficking of IL-2-activated 
lymphocytes into tumor nodules. It is therefore 
unclear to what extent the antitumor effects of IL-2 
can be dissociated from its toxicity, much of which 
may be mediated by inducible pyrogens such as 
TNF.
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